Daniel Chevallard was named President of LENZ Therapeutics, Inc. As of November 6, 2026, LENZ Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 2, 2026 to October 28, 2026, naming 1 appointment and 1 departure (Form 8-K, October 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like LENZ Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
LENZ Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-02 to 2026-10-28. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as LENZ Therapeutics, Inc. files it.
Layoffs on record: about 40 jobs, latest 2026-10-28 (layoff filings and notices).
Also on the record for LENZ Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 2% of the class | 5%+ stakes | Source |
| November 4, 2026 | Stake report, Schedule 13G, by BML Investment Partners, L.P. | 6.7% of the class | 5%+ stakes | Source |
| November 2, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 0.2% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 5.2% of the class | 5%+ stakes | Source |
| October 21, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 3.7% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.7% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.1% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.8% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G, by Squarepoint Ops LLC | 5.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Ridgeback Capital Investments L.P. | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.8% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs LENZ Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on LENZ Therapeutics, Inc. and the records around it.
LENZ Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices Oct 2026
- Who owns it
Companies that share a holder
- Squarepoint Ops LLC also filed stake reports on 1 other company: Cartesian Therapeutics, Inc. (Mar 2026)
- Ridgeback Capital Investments L.P. also filed stake reports on 3 other companies: Replimune Group, Inc. (Aug 2026), iTeos Therapeutics, Inc. (Nov 2025), Semler Scientific, Inc. (Nov 2025)
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), Monte Rosa Therapeutics, Inc. (Jan 2026), LAVA Therapeutics N.V. (Sep 2025)
Watch LENZ Therapeutics, Inc.
Get an email when LENZ Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on LENZ Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on LENZ Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LENZ Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 21 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | In | President | 8-K, 2026-10-28 | ||
| 2026-07-02 | Out | 8-K, 2026-07-02 |
Who leads LENZ Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Daniel Chevallard, appointed (filed 2026-10-28).
New leaders reset buying decisions — get the Full Report on LENZ Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at LENZ Therapeutics, Inc., with the record behind each one.
Find candidates like President at LENZ Therapeutics, Inc.Every change, in the filing's words
Appointed: Daniel Chevallard, President
Appointment of Interim President and Chief Executive Officer In connection with the transition described above, on October 28, 2026, the Board appointed Daniel Chevallard, the Company's Chief Financial Officer, to serve as the Company's Interim President and CEO and principal executive officer replacing Mr. Schimmelpennink in such roles, effective as of the CEO Transition Date.
- Resignation of President, Chief Executive Officer and Director On October 28, 2026, the Company announced that Evert Schimmelpennink, the Company's President and Chief Executive Officer ("CEO"), will transition from his roles as President and CEO effective December 1, 2026 (the "CEO Transition Date"), with Daniel Chevallard, the Company's current Chief Financial Officer, to succeed him as Interim President and CEO as of such date.
- Mr. Schimmelpennink will also resign from the Board effective as of the CEO Transition Date.
- Mr. Schimmelpennink will continue to serve as President and CEO of the Company on a full-time basis and as a member of the Board until the CEO Transition Date and will thereafter continue as a full time employee of the Company until December 31, 2026 (the "Separation Date"), serving as Strategic Advisor to the CEO from the CEO Transition Date through the Separation Date (the "Transition Period").
- Mr. Schimmelpennink's decision to resign as an officer and director of the Company was not the result of any dispute or disagreement between the Company and Mr. Schimmelpennink on any matter relating to the operations, policies, or practices of the Company.
- In connection with Mr. Schimmelpennink's decision to resign from the Board, on October 28, 2026, the Board approved a decrease in the size of the Board to five (5), effective as of the CEO Transition Date.
Departing: Zach Scheiner
On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the "Company") of his resignation as a member of the Company's Board of Directors (the "Board") and from all committees of the Board on which he served, effective immediately.
- Dr. Scheiner's resignation was not the result of any dispute or disagreement between the Company and Dr. Scheiner on any matter relating to the operations, policies or practices of the Company.
- Dr. Scheiner has been a valuable member of the Board and the Company expresses its appreciation for Dr. Scheiner's service and strong work as a member of the Board and the committees on which he served.
- On June 30, 2026, the Board decreased the size of the Board to six (6) as a result of Dr. Scheiner's resignation.
- Following the resignation of Dr. Scheiner, on June 30, 2026, the Board appointed Jeff George to its audit committee (the "Audit Committee").
- Effective upon such appointment, the members of the Audit Committee are Shelley Thunen, Frederic Guerard, and Jeff George.
Tools for this story
Each opens in a new tab, filled in for LENZ Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.